AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02035618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises + Manual Therapy
Description: Mobilization; massage; post-isometric relaxation; strengthening; stretching
Study NCT03586791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pupillometry guided anesthesia
Description: At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml.
Study NCT03586791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPI guided anesthesia
Description: During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
Study NCT03586791 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard management
Description: During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60.~Remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients.
Study NCT02777892 — intervention group
Intervention type: OTHER
Intervention: Sapien S3
Description: Patients that have undergone percutaneous implantation of an Edwards SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
Study NCT02228902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate
Description: one group receives ferrous fumarate (12 patients) and one group (12 patients) receives ferrous gluconate
Study NCT02228902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous gluconate
Description: One group receives ferrous fumarate and one group receives ferrous fumarate.
Study NCT03873753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleaning
Description: Gauze and mineral water
Study NCT03873753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No oral cleaning
Description: Absence of cleaning
Study NCT03801642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg oral tablets taken once daily for 12 weeks
Study NCT03801642 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (matched in size and color to active tablet) taken once daily for 12 weeks
Study NCT01789788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, multiple doses
Study NCT01789788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6811135
Description: multiple ascending doses
Study NCT02017275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA
Description: This group will contain 1175 subjects.
Study NCT02017275 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXCEL
Description: This group will contain 1175 subjects.
Study NCT01441128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066/PF-00299804
Description: Combined PF-02341066 and PF-00299804
Study NCT01441128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066/PF-00299804
Description: Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
Study NCT02926105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T&E Home-based exercise programme
Description: T\&E exercises programme consists of home-based individually tailored balance and functional strength tests and exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months.
Study NCT02926105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otago
Description: Otago exercises programme consists of home-based individually tailored balance, strength and walking exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months.
Study NCT02926105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Helsana booklet
Description: Helsana programme consists of a booklet with recommendations and 10 exercises performed 3x a week over 12 months.
Study NCT03256019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Intubation
Description: Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
Study NCT03625596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: Acute intervention (3 hours)
Study NCT03625596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: Acute intervention (3 hours)
Study NCT03625596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate / Nitrite
Description: Acute intervention (3 hours)
Study NCT03625596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute intervention (3 hours)
Study NCT03025633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PEARL
Description: PEARL, is a commercially available PC-based tool that provides a realistic and functional 3D model of a linac and, having uploaded example treatments it can demonstrate the treatment procedure and also relevant anatomical information.
Study NCT02287038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine 80 MG
Description: Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
Study NCT02287038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine 80 MG
Description: Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
Study NCT00689689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fully coated Prodigy stem
Description: Total hip arthroplasty with fully coated Prodigy stem
Study NCT00689689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Endurance Stem
Description: total hip arthroplasty with cemented endurance stem
Study NCT03260608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telesupport
Description: In the intervention will be carried out eight weekly phone calls of psychoeducation and support on the disease of the relatives approaching different themes.
Study NCT02848664 — intervention group
Intervention type: DEVICE
Intervention: Dysphagia retraining with device
Description: Patients used the device for 60 trials of retraining swallowing at home each day and also had the device turned on throughout the day in automatic mode to intermittently trigger every few minutes to trigger a swallow for saliva control
Study NCT02408198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety intervention
Description: The intervention is based on a brief CBT for psychosis (CBTp) programme, focusing on understanding and managing anxiety processes that contribute to persecutory threat beliefs when in busy urban environments. The novel aspect of this intervention is that it is delivered in a group format. The intervention consists of six sessions which will be delivered on a weekly basis. Throughout the intervention there is an emphasis on setting tasks to practice applying the new skills outside of sessions, to help the person build confidence in being able to manage paranoia and feel less distressed in their daily life.
Study NCT00953290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera Radio Frequency Device
Description: Up to three treatments, one pass, dosage range of 15-60 kJ.
Study NCT00263198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK222584
Study NCT00263198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT01419314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splinting application to the lower extremities
Description: Walkabout™ splints (Don Joy Orthopedics, Vista, CA, USA) will used in the splinting treatment. The Walkabout splint is a one-piece injection molded walking boot fitted with a rocker bottom allowing for ambulation. The participants will be fitted and instructed to wear the bilateral LE splints to sleep for the duration of the study (6 weeks).
Study NCT01419314 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Splint liner application
Description: The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study (6 weeks).
Study NCT01819727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMN 165
Description: After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.
Study NCT03050827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% oxybutynin
Description: Topical Gelnique 3%TM (3% oxybutynin) applied daily for 20 weeks in type 2 diabetic subjects with established peripheral neuropathy. Subjects will be randomized into placebo or active drug arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 by 2 region of skin adjacent to the initial biopsy site. Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance.
Study NCT03050827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active placebo for 3% oxybutynin
Study NCT04449289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine
Description: Intraoperatively and postoperatively a standard intravenous infusion of lidocaine will be used for analgesia
Study NCT02859129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg tablet
Description: Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
Study NCT02859129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova™ QD (2 x 1 g capsules)
Description: Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)
Study NCT02859129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose
Description: Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24
Study NCT02859129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple (20) oral doses of 2 g Vascepa® every 12 hours
Description: Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).
Study NCT00188942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine+Olanzapine
Study NCT00188942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Study NCT00188942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging
Study NCT03300505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRx
Description: Given intravenously (IV)
Study NCT04449289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural ropivacaine
Description: Intraoperatively and postoperatively an epidural infusion of ropivacaine will be used for analgesia
Study NCT03890458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEVIT-3
Description: The physicians gave the women in the experimental group vitamin D oral drops in an ampoule of 300,000 IU and a vial of 50,000 IU to take during the IVF treatment. Written and verbal information about how to take vitamin D was provided to the participants by the nurses. The women took 300,000 IU vitamin D orally for the first week. In the second week of the treatment, 50,000 IU vitamin D (15 drops/day) was used as maintenance dose until the pregnancy test day.
Study NCT02526485 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
Study NCT01733745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SYSTANE® Lid Wipes
Description: Pre-moistened eyelid cleansing wipes for topical ocular external scrubbing of eyelids and eyelashes
Study NCT01733745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SYSTANE® BALANCE
Description: Lubricant Eye Drops
Study NCT01733745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SYSTANE® Vitamins
Study NCT01733745 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microfiber towels (as warm compresses, with or without saline eye drops)
Study NCT05056961 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multiparametric mesurements
Description: Multiparametric assessments will necessitate the use of a plastic belt to record electro-impedancemetry tomography data; and a nano-gatsric tube fitted with esophageal and gastric low pressure balloons
Study NCT03300505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given by mouth (PO)
Study NCT03415373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Adapter (Model UAR-2S)
Description: Investigational device
Study NCT03415373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypodermic needle + syringe
Description: Control device
Study NCT03301441 — intervention group
Intervention type: OTHER
Intervention: questionnaire ef-ID Migraine
Description: All consecutive patients eligible to the study will be included within 7 days of their initial admission, and evaluated with a short questionnaire classifying them as migrainers whose status will undergo a detailed validation at 3 months by a migraine expert, and non-migrainers whose status will be validated by repeating the short questionnaire at the follow-up visit at 3 months.~Initial multimodal imaging, done routinely in any stroke patient, will acquire the raw data necessary to calculate the mismatch ratio (MRI DWI/PWI or CT rCBF/CTP). All radiological data will be analyzed centrally after the end of the recruitment, by investigators blinded to the migraine status.
Study NCT01254552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iobitridol
Description: Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
Study NCT01254552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadoterate meglumine
Description: Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
Study NCT04651790 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 inactivated vaccine
Description: The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
Study NCT04651790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 inactivated vaccine
Description: The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
Study NCT00683683 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Knowledge Translation
Description: The multifaceted KT strategy will include 1) local multidisciplinary champions in ED, ICU, and Cardiology 2) A simple protocol for application of hypothermia, tailored to local needs and policy; 3) Identification of perceived and actual barriers to knowledge use; 4) Development of an implementation tool kit and 5) Providing timely feedback on benchmarks for hypothermia and outcomes.
Study NCT03228628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed 50:50 mixture of nitrous oxide and oxygen
Description: Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
Study NCT03228628 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inhale medical air (22% O2 - 78% N2)
Study NCT04704583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPACE parental-guidance
Description: The treatment will be delivered to the parents in ten 50-minute sessions. The sessions are planned to be weekly and will be completed within 13 weeks of the first session. The sessions include instruction and education, acquiring skills, role-play, and simulations. Parents will be given exercises and goals in reducing accommodation to achieve at home (in cognitive behavioral therapy this is sometimes called 'homework') in some of the sessions. For example, parents to write down one or two things that they would most like to see their child handling better.
Study NCT04704583 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPACE parental-guidance
Description: The treatment will be delivered to the parents in ten 50-minute sessions. The sessions are planned to be weekly and will be completed within 13 weeks of the first session. The sessions include instruction and education, acquiring skills, role-play, and simulations. Parents will be given exercises and goals in reducing accommodation to achieve at home (in cognitive behavioral therapy this is sometimes called 'homework') in some of the sessions. For example, parents to write down one or two things that they would most like to see their child handling better.
Study NCT02103517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega -3 fatty acids
Description: Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.
Study NCT02103517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Corn oil
Description: Each subject assigned to the control group will receive 4 g/day capsule of corn oil.
Study NCT01310608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A-View
Description: Pre-operative imaging of the thoracic aorta with A-View technique
Study NCT03333213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gua Sha
Study NCT00845962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chloroprocaine
Description: spinal administration of chloroprocaine 2%, 40 mg (2 mL)
Study NCT00845962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
Study NCT02374723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuCornea
Description: Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea
Study NCT02374723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: donated human corneas
Description: Deep anterior lamellar corneal transplantation with a donated cornea as graft material.
Study NCT01956604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study NCT01956604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo